NX006 is a leading treatment in pain management with annual sales exceeding £340m in 2009. However, patients treated using the currently marketed form require a high daily dosage of over 3000 mg of this very low solubility API.

In-vivo testing of the new solid forms of NX006 created by Nuformix demonstrate an increase of up to 220% in bioavailability. Across the range of forms studied, the results conclusively demonstrate that dramatic reductions in patient dosage are achievable, as are improved release profiles and more cost-effective manufacturing.

These options are made possible by Nuformix simply via re-engineering of the solid form and were expected following significant physical property changes when compared to the parent compound.

Nuformix have therefore completed critical steps in its strategy to discover, scale-up and validate vastly improved forms of currently marketed drug products and is currently seeking collaborative partnerships to enable market approval of this product.

With current annual sales growing to over £240m in 2009, NX007 is currently in late stage clinical trials for numerous new indications. The novel solid forms of NX007, re-engineered by Nuformix, offer greatly increased bioavailability for this very poorly water soluble drug.

The existing year-on-year sales growth of NX007 and high likelihood of approval for important new indications combine to make this filing a critical step forward for Nuformix in delivering against it’s strategy. As with NX006, the NX007 patent application was conceived together with Jeffrey A. Lindeman at the firm J. A. Lindeman LLC.

NX006 is a leading muscle relaxant with annual sales exceeding £340m in 2009. The novel solid forms of NX006, re-engineered by Nuformix, offer new options in terms of achieving increased bioavailability of this highly insoluble drug.

The patent application was conceived together with Jeffrey A. Lindeman who is an esteemed Intellectual Property consultant and world renowned thought leader in the field of legal issues relating to pharmaceutical solid form at the firm J. A. Lindeman LLC.

Nuformix will immediately benefit from increased autonomy and flexibility across all stages of its product development process from discovery to characterisation and subsequent scale-up.

In addition, this additional funding will enable Nuformix to take its products further up the value chain, creating greater value by de-risking products for customers. Overall, GRD funding will enable a more rapid development plan that will deliver higher-value products than would have otherwise been possible.

Initial activities will focus on solid form optimisation studies across a range of current drugs identified as having sub-optimal performance as a result of poor solid form selection. It is expected that the funds raised will be sufficient to complete an extensive R&D programme in addition to product validation and out-licensing activities.

This first phase of Nuformix’s existence will validate the value of solid form in shortening product development cycles, reducing risk in product development and the creation of new opportunities in life cycle management and drug reprofiling.